Digest Network Come funziona
Network
/
Società
Co
Non verificato

Contineum Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieMercato azionarioSalute

38 comunicati stampa

Guarda tutti i comunicati
30/06/2026
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry
Fonte
Contineum Therapeutics, Inc.
Emittente
Business Wire
1.00
0
01/06/2026
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Eventi
Web e Social Network
Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference
Fonte
Contineum Therapeutics, Inc.
Emittente
Business Wire
1.00
0
15/05/2026
Mercato azionario
Finanza
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Contineum Therapeutics, Inc.
Emittente
Business Wire
1.00
0
12/05/2026
Web e Social Network
Fiere
Eventi
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference
Fonte
Contineum Therapeutics, Inc.
Emittente
Business Wire
1.00
0
11/05/2026
Eventi
Web e Social Network
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference
Fonte
Contineum Therapeutics, Inc.
Emittente
Business Wire
1.00
0
05/05/2026
Mercato azionario
Biotecnologia
Sanità
Salute
Farmaceutica
Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
Fonte
Contineum Therapeutics, Inc.
Emittente
Business Wire
1.00
0
01/05/2026
Mercato azionario
Finanza
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Contineum Therapeutics, Inc.
Emittente
Business Wire
1.00
0
30/04/2026
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain
Fonte
Contineum Therapeutics, Inc.
Emittente
Business Wire
1.00
0
13/03/2026
Mercato azionario
Finanza
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Contineum Therapeutics, Inc.
Emittente
Business Wire
1.00
0
05/03/2026
Mercato azionario
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
Fonte
Contineum Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0